Recursion Pharmaceuticals (NASDAQ: RXRX) is doing so specifically within the biotech niche, but the company's efforts haven't ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predi ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals reported Q1 2026 progress on its AI-driven drug discovery programs, highlighting its first clinical proof of concept and multiple upcoming trial readouts. The company has ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 ...

Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ: RXRX), announced today that its portfolio companies have collectively raised more than $205 million in ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.